Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
出版信息
Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8.
PMID:27508349
Abstract
摘要
相似文献
1
Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8.
2
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
3
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
Am Fam Physician. 2017 May 15;95(10):664-666.
4
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
5
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.
6
[Proposal for a simple scheme of direct-action antivirals for HCV treatment in a low budget public health system].
Salud Publica Mex. 2018 Nov-Dic;60(6):738-740. doi: 10.21149/9492.
7
New Drug Treats All Genotypes of Chronic HCV.
Am J Nurs. 2016 Oct;116(10):27. doi: 10.1097/01.NAJ.0000503296.12853.3e.
8
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Drugs Today (Barc). 2018 Apr;54(4):255-268. doi: 10.1358/dot.2018.54.4.2788017.
9
Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
Drugs Today (Barc). 2017 Mar;53(3):177-189. doi: 10.1358/dot.2017.53.3.2604176.
10
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.
Zotero 插件